Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci
Vancomycin-resistant enterococci (VRE) account for a large proportion of hospital-acquired infections. Determining optimal treatment of VRE urinary tract infections (UTIs) is challenging. The purpose of this study was to determine if a difference in efficacy or safety exists between linezolid and no...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | English |
| Publicado: |
MDPI AG
2021-10-01
|
| Colección: | Pharmacy |
| Materias: | |
| Acceso en línea: | https://www.mdpi.com/2226-4787/9/4/175 |
| _version_ | 1827670277950013440 |
|---|---|
| author | Mary Joyce Wingler Neel R. Patel S. Travis King Jamie L. Wagner Katie E. Barber Kayla R. Stover |
| author_facet | Mary Joyce Wingler Neel R. Patel S. Travis King Jamie L. Wagner Katie E. Barber Kayla R. Stover |
| author_sort | Mary Joyce Wingler |
| collection | DOAJ |
| description | Vancomycin-resistant enterococci (VRE) account for a large proportion of hospital-acquired infections. Determining optimal treatment of VRE urinary tract infections (UTIs) is challenging. The purpose of this study was to determine if a difference in efficacy or safety exists between linezolid and non-linezolid treatments for VRE UTIs. This retrospective cohort evaluated patients admitted between 1 June 2012–30 November 2017 who were treated for VRE UTI. Patients must have had at least one sign, symptom, or laboratory confirmation of UTI to be included. The primary endpoint of this study was difference in clinical cure between linezolid and non-linezolid treatment options. Secondary endpoints included 30-day recurrence, 30-day infection-related readmission, inpatient mortality, infection-related hospital length of stay (LOS), and time to appropriate therapy. A total of 45 patients (33 linezolid and 12 non-linezolid) were included. Clinical cure occurred in 71.4% linezolid and 58.3% non-linezolid (<i>p</i> = 0.476). No patients had a 30-day infection-related readmission or 30-day recurrence. Of the 45 patients, 6 (13.3%) patients died during admission, and 5 of those deaths were in the linezolid group (<i>p</i> = 1.000). No significant difference was found for clinical cure between linezolid and non-linezolid treatment options for VRE UTIs. |
| first_indexed | 2024-03-10T03:18:46Z |
| format | Article |
| id | doaj.art-c6fd6f3e8d0a4fa2a236c491e3ad9252 |
| institution | Directory Open Access Journal |
| issn | 2226-4787 |
| language | English |
| last_indexed | 2024-03-10T03:18:46Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmacy |
| spelling | doaj.art-c6fd6f3e8d0a4fa2a236c491e3ad92522023-11-23T10:07:35ZengMDPI AGPharmacy2226-47872021-10-019417510.3390/pharmacy9040175Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant EnterococciMary Joyce Wingler0Neel R. Patel1S. Travis King2Jamie L. Wagner3Katie E. Barber4Kayla R. Stover5Department of Antimicrobial Stewardship, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USADepartment of Pharmacy, Baptist Health Care, 1000 W Morena St, Pensacola, FL 32501, USADepartment of Pharmacy, Ochsner Medical Center, 1514 Jefferson Hwy, New Orleans, LA 70121, USADepartment of Pharmacy Practice, University of Mississippi School of Pharmacy, 2500 North State Street, Jackson, MS 39216, USADepartment of Pharmacy Practice, University of Mississippi School of Pharmacy, 2500 North State Street, Jackson, MS 39216, USADepartment of Pharmacy Practice, University of Mississippi School of Pharmacy, 2500 North State Street, Jackson, MS 39216, USAVancomycin-resistant enterococci (VRE) account for a large proportion of hospital-acquired infections. Determining optimal treatment of VRE urinary tract infections (UTIs) is challenging. The purpose of this study was to determine if a difference in efficacy or safety exists between linezolid and non-linezolid treatments for VRE UTIs. This retrospective cohort evaluated patients admitted between 1 June 2012–30 November 2017 who were treated for VRE UTI. Patients must have had at least one sign, symptom, or laboratory confirmation of UTI to be included. The primary endpoint of this study was difference in clinical cure between linezolid and non-linezolid treatment options. Secondary endpoints included 30-day recurrence, 30-day infection-related readmission, inpatient mortality, infection-related hospital length of stay (LOS), and time to appropriate therapy. A total of 45 patients (33 linezolid and 12 non-linezolid) were included. Clinical cure occurred in 71.4% linezolid and 58.3% non-linezolid (<i>p</i> = 0.476). No patients had a 30-day infection-related readmission or 30-day recurrence. Of the 45 patients, 6 (13.3%) patients died during admission, and 5 of those deaths were in the linezolid group (<i>p</i> = 1.000). No significant difference was found for clinical cure between linezolid and non-linezolid treatment options for VRE UTIs.https://www.mdpi.com/2226-4787/9/4/175infectious diseasesanti-infectivesgenitourinaryenterococcusvancomycin-resistantlinezolid |
| spellingShingle | Mary Joyce Wingler Neel R. Patel S. Travis King Jamie L. Wagner Katie E. Barber Kayla R. Stover Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci Pharmacy infectious diseases anti-infectives genitourinary enterococcus vancomycin-resistant linezolid |
| title | Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci |
| title_full | Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci |
| title_fullStr | Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci |
| title_full_unstemmed | Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci |
| title_short | Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci |
| title_sort | linezolid for the treatment of urinary tract infections caused by vancomycin resistant enterococci |
| topic | infectious diseases anti-infectives genitourinary enterococcus vancomycin-resistant linezolid |
| url | https://www.mdpi.com/2226-4787/9/4/175 |
| work_keys_str_mv | AT maryjoycewingler linezolidforthetreatmentofurinarytractinfectionscausedbyvancomycinresistantenterococci AT neelrpatel linezolidforthetreatmentofurinarytractinfectionscausedbyvancomycinresistantenterococci AT stravisking linezolidforthetreatmentofurinarytractinfectionscausedbyvancomycinresistantenterococci AT jamielwagner linezolidforthetreatmentofurinarytractinfectionscausedbyvancomycinresistantenterococci AT katieebarber linezolidforthetreatmentofurinarytractinfectionscausedbyvancomycinresistantenterococci AT kaylarstover linezolidforthetreatmentofurinarytractinfectionscausedbyvancomycinresistantenterococci |